Trial of Afatinib in Pediatric Tumours

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 29, 2015

Primary Completion Date

August 5, 2020

Study Completion Date

August 5, 2020

Conditions
Neuroectodermal TumorsRhabdomyosarcoma
Interventions
DRUG

afatinib

Trial Locations (28)

1090

AKH - Medical University of Vienna, Vienna

St. Anna Children-Hospital, Children's Cancer Research, Wien, Vienna

2031

Sydney Childrens Hospital, Randwick

2100

Rigshospitalet, København, Børneonkologisk Afsnit 5002, København Ø

13353

Charité - Universitätsmedizin Berlin, Berlin

16147

Istituto G. Gaslini, Genova

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

28009

Hospital Infantil Universitario Niño Jesus, Madrid

31059

HOP Toulouse, Pédiat, Toulouse, Toulouse

33076

HOP Pellegrin, Bordeaux

35128

Azienda Ospedaliera Universitaria di Padova, Padua

45147

Universitätsklinikum Essen AöR, Essen

53792

University of Wisconsin, Madison

59020

CTR Oscar Lambret, Lille

69008

CTR Leon Berard, Lyon

72076

Universitätsklinikum Tübingen, Tübingen

75248

INS Curie, Paris

77030

The University of Texas Health Science Center at Houston, Houston

94805

INS Gustave Roussy, Villejuif

02215

Dana-Farber Cancer Institute, Boston

M5G 1X8

The Hospital for Sick Children, Toronto

00165

Osp. Pediatrico Bambin Gesù, Roma

3015 CN

Erasmus MC - Sophia Kinderziekenhuis, Rotterdam

08035

Hospital Vall d'Hebron, Barcelona

B4 6NH

Birmingham Children's Hospital, Birmingham

WC1N 3BN

Great Ormond Street Hospital, London

M13 9WL

Royal Manchester Children's Hospital, Manchester

SM2 5PT

The Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY